dihydralazine

{{Short description|Chemical compound}}

{{Redirect-distinguish|Nepresso|Nespresso}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 460786592

| IUPAC_name = 4-Hydrazinyl-1-hydrazinylidene-1,2-dihydrophthalazine

| image = Dihydralazine.svg

| width = 125

| image2 = Dihydralazine-3D-balls.png

| width2 = 125

| tradename =

| Drugs.com = {{drugs.com|international|dihydralazine}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 484-23-1

| ATC_prefix = C02

| ATC_suffix = DB01

| PubChem = 10230

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 9813

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = PCU411F5L6

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D07170

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 35505

| C=8 | H=10 | N=6

| smiles = NNc1c2ccccc2C(=NN)Nn1

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = VQKLRVZQQYVIJW-UHFFFAOYSA-N

}}

Dihydralazine is a prescription drug{{Cite web |title=Dihydralazine - Uses, Side Effects, Substitutes, Composition And More |url=https://www.lybrate.com/medicine/dihydralazine/ |access-date=2024-03-25 |website=Lybrate |language=en}} with antihypertensive properties.{{cite journal | vauthors = Stern HC, Matthews JH, Belz GG | title = Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects | journal = British Heart Journal | volume = 52 | issue = 4 | pages = 435–9 | date = October 1984 | pmid = 6477782 | pmc = 481656 | doi = 10.1136/hrt.52.4.435 }} It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally, and is available in the form of tablets. It belongs to the hydrazinophthalazine chemical class.{{cite journal | vauthors = Bourreli B, Pinaud M, Passuti N, Gunst JP, Drouet JC, Remi JP | title = Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion | journal = Canadian Journal of Anaesthesia | volume = 35 | issue = 3 ( Pt 1) | pages = 242–8 | date = May 1988 | pmid = 3383316 | doi = 10.1007/BF03010617 | doi-access = free }} It has very similar effects to hydralazine.